Results 131 to 140 of about 4,028 (164)

A stochastic modeling study of H56 block in Daqingzijing oilfield

Arabian Journal of Geosciences, 2015
After years of water injection, the underground movement of oil and water in Daqingzijing oilfield is becoming more and more complex, and the distribution of reservoir parameters between wells and remaining oil is difficult to predict. The reservoir geological model of H56 block in Daqingzijing oilfield is established with the support of numerous data ...
Jianpeng Hou, Fang Ding, Weilu Li
openaire   +1 more source

Antiarrhythmic Properties of Stereoisomers of a Beta-adrenergic Blocking Agent (H56/28)

Anesthesiology, 1968
Cardiac arrhythmias were produced in the cat by inhalation of 1 per cent halopropane, 10 per cent CO2 and 89 per cent O2 and also by injection of epinephrine during inhalation of 1 per cent halopropane and 99 per cent O2. Dextro-H56/28, which has local anesthetic properties but only 1/40th the beta receptor blocking activity of the levo form of H56/28,
C O, Lord, R L, Katz, K E, Eakins
openaire   +2 more sources

H56 Driving performance of huntington’s disease gene carriers

Clinical care and clinical services, 2018
Background In patients with Huntington’s disease (HD), instrumental daily activities such as working and driving become affected at a relatively young age. For most patients, the decision to quit driving is difficult and affects their independence and social activities.
Milou Jacobs, Ellen P Hart, Yuri Mejia Miranda, Geert Jan Groeneveld, Joop MA van Gerven, Raymund AC Roos   +5 more
openaire   +1 more source

Immunogenicity of TB vaccine H56 in non-human primates (VAC4P.1113)

The Journal of Immunology, 2015
Abstract Tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb), remains a major global health problem. Several TB vaccine candidates are currently in various stages of development and clinical testing, including the protein subunit vaccine H56, from Statens Serum Institute (Copenhagen, Denmark).
Eileen Wong, Else Agger, Peter Andersen, JoAnne Flynn   +3 more
openaire   +1 more source

H1- and H56- subunit vaccines against TB - an overview of the clinical development

European Respiratory Journal, 2014
Despite a very effective worldwide vaccination program, BCG vaccination has proven to be insufficient to provide protection against TB disease, and a better vaccine is urgently needed. Statens Serum Institut has developed two TB vaccine candidates, H1:IC and its improved successor H56:IC.
Morten Ruhwald, Else Marie Agger, Søren T. Hoff, Peter L. Andersen   +3 more
openaire   +1 more source

TWO NEW ESCHERICHIA COLI O ANTIGENS, O162 AND O163, AND ONE NEW H ANTIGEN, H56. WITHDRAWAL OF H ANTIGEN H50

Acta Pathologica Microbiologica Scandinavica Section B Microbiology, 1975
Three E. coli strains representing strains from faeces of normal persons were established as antigenic test strains of two new O antigens, O162 and O163, and one new H antigen, H56.
F Ørskov, I Ørskov, K A Bettelheim
exaly   +3 more sources

Dose Optimization of H56:IC31 Vaccine for Tuberculosis-Endemic Populations. A Double-Blind, Placebo-controlled, Dose-Selection Trial

American Journal of Respiratory and Critical Care Medicine, 2019
Abstract Rationale Global tuberculosis (TB) control requires effective vaccines in TB-endemic countries, where most adults are infected with Mycobacterium tuberculosis (M.tb). Objectives We sought to define optimal ...
Sara Suliman, Angelique Kany Kany Luabeya, Hennie Geldenhuys, Michele Tameris, Soren T. Hoff, Zhongkai Shi, Dereck Tait, Ingrid Kromann, Morten Ruhwald, Kathryn Tucker Rutkowski, Barbara Shepherd, David Hokey, Ann M. Ginsberg, Willem A. Hanekom, Peter Andersen, Thomas J. Scriba, Mark Hatherill   +16 more
openaire   +2 more sources

Mucosal boosting of H56:CAF01 immunization promotes lung-localized T cells and an accelerated pulmonary response to Mycobacterium tuberculosis infection without enhancing vaccine protection [PDF]

Mucosal Immunology, 2019
T cell-mediated protection against Mycobacterium tuberculosis (Mtb) is dependent upon the ability to localize within the site of pulmonary infection and directly interact with infected cells. In turn, vaccine strategies to improve rapid T cell targeting of Mtb-infected cells after pulmonary exposure are being actively pursued.
Joshua S Woodworth, Peter Andersen, Joseph P Cassidy   +2 more
exaly   +5 more sources

First-in-human trial of the post-exposure tuberculosis vaccine H56:IC31 in Mycobacterium tuberculosis infected and non-infected healthy adults

Vaccine, 2015
H56:IC31 is a candidate tuberculosis vaccine comprising a fusion protein of Ag85B, ESAT-6 and Rv2660c, formulated in IC31 adjuvant. This first-in-human, open label phase I trial assessed the safety and immunogenicity of H56:IC31 in healthy adults without or with Mycobacterium tuberculosis (M.tb) infection.Low dose (15 μg H56 protein in 500 nmol IC31 ...
Angelique Kany Kany, Luabeya, Benjamin M N, Kagina, Michele D, Tameris, Hennie, Geldenhuys, Soren T, Hoff, Zhongkai, Shi, Ingrid, Kromann, Mark, Hatherill, Hassan, Mahomed, Willem A, Hanekom, Peter, Andersen, Thomas J, Scriba, Elisma, Schoeman, Colleen, Krohn, Cheryl L, Day, Hadn, Africa, Lebohang, Makhethe, Erica, Smit, Yolande, Brown, Sara, Suliman, E Jane, Hughes, Peter, Bang, Margaret A, Snowden, Bruce, McClain, Gregory D, Hussey   +24 more
openaire   +2 more sources

H56 Comparison of the efficacy and safety of candesartan cilexetil 4, 8 and 12 mg with placebo and enalapril 10 mg in patients with mild to moderate essential hypertension [PDF]

American Journal of Hypertension, 1997
exaly   +2 more sources